Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLIMACTERIC”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 955 records · Page 53Linked to original sources
PubMed1984

A continuous estrogen-progestogen regimen for climacteric complaints. Effects on lipid and lipoprotein metabolism.

The lipid composition of serum and the lipoprotein fractions, very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) were determined in 26 peri- and postmenopausal women treated with a daily dose of 2 mg 17-beta-estradiol, 1 mg estriol and 1 mg norethisteroneacetate in a continuous regimen for 12 months. A decrease was noted in all serum lipids, triglycerides, cholesterol and phospholipids during treatment. When comparing the lipid values after 3 and 12 months of treatment a tendency was found to approach pretreatment values with time. A reduction of triglycerides in VLDL after 3 months, concomitant with a decrease in HDL-cholesterol, was interpreted as an effect mainly of the progestogen component. A decrease of free cholesterol in LDL was found during treatment. The ratio of LDL-cholesterol/HDL-cholesterol was unaltered when comparing values before vs. after 3 and 12 months of treatment. Decreased levels of HDL-cholesterol and elevated levels of LDL-cholesterol are considered to be risk factors for coronary heart disease. The significance of lipid metabolic effects induced by treatment in the present study on a longterm basis is hard to evaluate in terms of atherogenicity.

Adult↗
PubMed1986

The epidemiology of climacteric symptoms.

The purpose of this study was to investigate symptoms of estrogen deficiency, androgen excess and urinary incontinence in a representative sample of middle-aged women. A sample consisting of 1746 women aged 40-66 was randomly selected. Of those initially selected, 1413 (81%) were eventually investigated. Gynecological data were obtained by means of questionnaires. 53% of the menstruating and 79% of the naturally postmenopausal women reported one or more symptoms indicating estrogen deficiency. 40% of the postmenopausal women had experienced marked vasomotor symptoms. Symptoms of androgen excess were uncommon. The occurrence of urinary incontinence was 10%.

Adult↗
PubMed1986

Serum lipoprotein changes in climacteric women induced by sequential therapy with natural estrogens and medroxy-progesterone acetate or norgestrel.

Thirty perimenopausal women were randomized to sequential therapy with either estradiol-valerate and norgestrel (Cyclo-Progynon), or estradiol and medroxy-progesterone acetate (EM 627). Blood samples were drawn before treatment and in the third treatment cycle during estrogen and progestogen phases respectively. The clinical effects of the two treatments were without significant difference. Ovulation was not suppressed by the treatments, which induced similar increases in serum estradiol and estrone concentrations. The medium serum high density lipoprotein-(HDL)-cholesterol concentration expressed as a percentage of the pretreatment level decreased in the postmenopausal women treated with Cyclo-Progynon to 90% compared with 104% (p less than 0.01) in the EM 627 group. However, the concentrations expressed in mmol/l did not differ significantly, probably owing to non-significant differences in the pretreatment levels. Low density lipoprotein-(LDL)-cholesterol concentrations decreased by approximately 10% in the postmenopausal women during both treatments. Cyclic addition of medroxy-progesterone acetate to estrogen replacement therapy does not adversely affect the serum lipoprotein pattern, and may be preferable to norgestrel.

Adult↗
PubMed2000

Management of the climacteric. Options abound to relieve women's midlife symptoms.

The transition out of the reproductive years can often be accompanied by uncomfortable and disruptive symptoms, one of the most common of which is hot flashes. Drs Morrissey and Kirchner describe this and other typical menopausal symptoms, as well as pharmacologic, hormonal, and lifestyle options that can bring relief and enable a smooth midlife passage.

Climacteric↗
PubMed1999

[Climacteric and quality of life].

BACKGROUND: Menopause is for women a critical period of their life, in which organic troubles and psychological problems cherish themselves. With particular reference to hot flushes and impaired sleep (the frequently found troubles), the benefits of physical exercise in women of this age have been evaluated. METHODS: A study based on a questionnaire has been carried out on 79 women of age between 51 and 58 (who practised regular physical activity, selected at sporting centers), and 481 women of age between 52 and 58, selected between patients who came to the University Hospital for reasons not ascribed to menopause. All the women selected in the study underwent to natural menopause, and didn't use hormonal therapy. The questionnaire evaluated symptomatology and its level of severity. RESULTS: In the first group 57% of the women didn't report symptoms, 30% light symptoms, 12% medium, 1% severe. In the second group 52% didn't report symptoms, 15% light symptoms, 22% medium, 11% severe. CONCLUSIONS: Besides verifying a bigger well-being among women who practice physical activity, the interesting result is that 52% of the second group didn't refer symptomatology. The advantages of a balanced diet, with particular attention to food with phytoestrogens, is discussed and the psychosocial problems of woman in menopause, covering a fundamental role to explain a great part of the symptomatology, are underlined. Finally, the guide lines for a right preparation to menopause are presented.

Climacteric↗